Rationale and protocol design for the TORG1835/NEXT-SHIP study: a phase II study of carboplatin, etoposide and nintedanib for unresectable limited/extensive disease small cell lung cancer with idiopathic pulmonary fibrosis.

Satoshi IkedaTakashi OguraTerufumi KatoHirotsugu KenmotsuTae IwasawaToshihiro MisumiTakeharu YamanakaHiroaki Okamoto

Published in: Therapeutic advances in medical oncology (2020)

Japan Registry of Clinical Trials, jRCTs031190119, registered date: October 18, 2019 - Retrospectively registered, https://jrct.niph.go.jp/en-latest-detail/jRCTs031190119.

Keyphrases

idiopathic pulmonary fibrosis
phase ii study
locally advanced
small cell lung cancer
clinical trial
open label
interstitial lung disease
rectal cancer
squamous cell carcinoma
randomized controlled trial
radiation therapy
rheumatoid arthritis
systemic sclerosis